Navigation Links
Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas
Date:9/28/2007

NEW ORLEANS, Sept. 28 /PRNewswire/ -- Sanarus Medical today announced a partnership with leading breast care physicians from select centers across the country. These Centers, including breast care physicians from Connecticut to California, will work in partnership with Sanarus to increase the awareness and availability of an innovative, non-surgical treatment option for women with benign breast tumors, known as fibroadenomas. Sanarus will host a gathering of these new Centers prior to the American College of Surgeons (ACS) annual meeting in New Orleans.

In partnership with Sanarus, these centers will participate in regional and national efforts to increase patient and primary care physician awareness of the Visica 2 treatment as a minimally invasive, highly safe and effective treatment alternative to surgical excision. These Centers will participate in a patient registry to document the clinical outcomes and patient satisfaction rates following Visica 2 treatment.

Additionally, these Centers are dedicated to expanding private health insurance coverage of this important treatment option, making it more widely available to women across the country. Sanarus plans to include as many as 20 centers in this program before the end of 2007.

"I am very pleased to be a part of this important program that will offer more options to my patients. This technology makes cryoablation easier and faster than ever before and not only does that make sense for my practice, it makes the procedure very appealing to my patients," said Andrew Kenler, M.D., a surgeon from Connecticut and one of the newly created Visica 2 Reference Centers.

Visica 2 Treatment System

The original Visica(R) Treatment System received FDA market clearance in 2002 and has been proven highly safe and effective with more than 1,500 fibroadenomas treated. The innovative Visica 2 System has been available at select sites since April of 2007. The Visica 2 Treatment System uses liquid nitrogen as the freezing agent, obviating the need for large, high pressure tanks of argon and helium used in the original Visica Treatment System. Because nitrogen operates at colder temperatures than argon, it allows for a more efficient, faster treatment. The procedure can be completed in the physician's office, with most treatment times under 15 minutes. Early experience has shown excellent physician and patient satisfaction with the new Visica 2 Treatment System.

Sanarus will be demonstrating this ground breaking system at the American College of Surgeons (ACS) meeting, October 7-11 in New Orleans.

Sanarus Medical is based in Pleasanton, CA and is focused on providing patients and physicians with minimally invasive, office-based breast care management solutions from diagnosis and treatment to follow up. Using cryoablation technology, Sanarus has developed proprietary technologies to provide breast surgeons and radiologists with a comprehensive and minimally invasive way to diagnose and treat breast patients. The Sanarus technologies change the way that patients are managed, from an operating room-based, surgically intensive care pathway to a more comfortable, cost effective, office-based care pathway. Sanarus is dedicated to women's breast health and to providing minimally invasive solutions for the diagnosis and treatment of breast disease solutions that can help eliminate pain and improve quality of life. The company's website is http://www.sanarus.com.


'/>"/>
SOURCE Sanarus Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg ... life. Although frozen embryos have a slight statistical advantage for live births, frozen ... a wonderful opportunity for women undergoing medical treatment or who are concerned about ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for ... 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device ... of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... 21, 2017 , ... Innovatum will demonstrate capabilities of fully ... Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses ... patient safety. , Microscan , a global technology leader in barcoding, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: